Trial Information

A Pilot Study of Differentiation Therapy in Multiple Myeloma Using Interleukin-6 and Interferon-a

OBJECTIVES:

- Determine the response rate in patients with recurrent multiple myeloma treated with
recombinant interferon alfa and recombinant interleukin-6.

- Determine the safety and optimal dose of this regimen in these patients.

- Determine the toxicity of this regimen in these patients.

- Determine the impact of this regimen on clonogenic growth of myeloma cells in serial in
vitro assays.

OUTLINE: This is a pilot study.

Patients receive recombinant interferon alfa subcutaneously (SC) once daily. Beginning 1
month later, patients also receive recombinant interleukin-6 SC once daily. Treatment
continues for up to 6 months in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 27 patients will be accrued for this study.